Athena Pharmaceutiques Overview
- Year Founded
-
2011

- Status
-
Private
- Employees
-
165

- Latest Deal Type
-
Debt
- Financing Rounds
-
3
- Investments
-
2
Athena Pharmaceutiques General Information
Description
Manufacturer and developer of pharmaceutical products intended to serve the pharma sector. The company specializes in manufacturing, safety, and environmental standards and can process most dosage forms such as bilayer tablets, capsules, sachets, sticks, effervescent tablets, and more.
Contact Information
Website
www.athenapharmaceutiques.comCorporate Office
- Espace Arnold de Ville
- 12 rue Georges Blandon
- 78430 Louveciennes
- France
Corporate Office
- Espace Arnold de Ville
- 12 rue Georges Blandon
- 78430 Louveciennes
- France
Athena Pharmaceutiques Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Athena Pharmaceutiques Comparisons
Industry
Financing
Details
Athena Pharmaceutiques Competitors (2)
One of Athena Pharmaceutiques’s 2 competitors is Nemera, a Private Equity-Backed company based in Lyon, France.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Nemera | Private Equity-Backed | Lyon, France | ||||
LTS Lohmann Therapie-Systeme | Private Equity-Backed | Andernach, Germany |
Athena Pharmaceutiques Patents
Athena Pharmaceutiques Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4491174-A1 | Mesalazine extended release composition and process for preparation thereof | Pending | 02-May-2023 | ||
EP-4265242-A1 | High dose tranexamic acid composition and process for preparation thereof | Pending | 20-Apr-2022 | ||
EP-4056171-A1 | Taste masked racecadotril tablet composition and process for preparation thereof | Inactive | 12-Mar-2021 | ||
CA-3105724-A1 | An orally disintegrating pharmacutical composition comprising nefopam and process for preparing the same | Inactive | 21-Jan-2020 | ||
US-20210220373-A1 | Orally disintegrating pharmacutical composition comprising nefopam and process for preparing the same | Inactive | 21-Jan-2020 | A61K9/0056 |
Athena Pharmaceutiques Signals
Athena Pharmaceutiques Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Athena Pharmaceutiques Acquisitions (2)
Athena Pharmaceutiques’s most recent deal was a Merger/Acquisition with Inpharmasci. The deal was made on 15-Jan-2020.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Inpharmasci | 15-Jan-2020 | Merger/Acquisition | Pharmaceuticals | ||
Ethypharm India | 28-Feb-2011 | Merger/Acquisition | Drug Delivery |
Athena Pharmaceutiques FAQs
-
When was Athena Pharmaceutiques founded?
Athena Pharmaceutiques was founded in 2011.
-
Where is Athena Pharmaceutiques headquartered?
Athena Pharmaceutiques is headquartered in Louveciennes, France.
-
What is the size of Athena Pharmaceutiques?
Athena Pharmaceutiques has 165 total employees.
-
What industry is Athena Pharmaceutiques in?
Athena Pharmaceutiques’s primary industry is Pharmaceuticals.
-
Is Athena Pharmaceutiques a private or public company?
Athena Pharmaceutiques is a Private company.
-
What is Athena Pharmaceutiques’s current revenue?
The current revenue for Athena Pharmaceutiques is
. -
How much funding has Athena Pharmaceutiques raised over time?
Athena Pharmaceutiques has raised $1.47M.
-
Who are Athena Pharmaceutiques’s investors?
Scale Up Capital has invested in Athena Pharmaceutiques.
-
Who are Athena Pharmaceutiques’s competitors?
Nemera and LTS Lohmann Therapie-Systeme are competitors of Athena Pharmaceutiques.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »